Oslo, Norway - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, is pleased to invite investors, analysts, and stakeholders to a live webcast event at 9:30 AM CET on Thursday, 26 February 2026.
During the webcast, Oncoinvent's management team will present a corporate update and discuss the company's financial results for the second half of 2025.
Second half 2025 webcast
Date: Thursday, 26 February 2026
Time: 9:30am CET
Webcast link: https://qcnl.tv/p/l-V8RQZomSSettvFIGnxjg
Relevant presentation material will on the same day be made available on the Investor Relations section of the Company's website at www.oncoinvent.com. A recording of the webcast will be made available after the live sending.
Contact:
Tel: 47 22183305
Email: oncoinvent@oncoinvent.com
(C) 2026 Electronic News Publishing, source ENP Newswire